StoxInfinium Pharmachem Limited
NSE: INFINIUM · Unclassified
Ask the data
Instant answers about Infinium Pharmachem Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY24 | FY25 | FY26 | |
|---|---|---|---|
| Revenue | 135.7 | 155.7 | 189.6 |
| EBITDA | 18.5 | 16.4 | 21.6 |
| Operating margin | 13.7% | 10.5% | 11.4% |
| Interest | 2.2 | 3.7 | 2.8 |
| Depreciation | 2.7 | 3.3 | 3.1 |
| Profit before tax | 15.2 | 11.6 | 17.8 |
| Tax | 3.7 | 3.7 | 3.6 |
| Net profit | 0.0 | 8.2 | 12.2 |
| EPS ₹ | 8.12 | 5.60 | 7.80 |
| Operating cash flow | -13.0 | -29.2 | 33.7 |
| Capex | 3.5 | 8.7 | 9.7 |
| Dividend paid | 0.0 | 0.0 | 0.0 |
| Total assets | — | 198.4 | 174.9 |
| Equity | — | 109.5 | 121.0 |
Half-yearly performance
last 6 half years · ₹ crore| H1 FY24 | H2 FY24* | H1 FY25 | H2 FY25 | H1 FY26 | H2 FY26 | |
|---|---|---|---|---|---|---|
| Revenue | 61.5 | 74.2 | 83.0 | 72.7 | 84.0 | 105.6 |
| Operating profit | 10.3 | 8.3 | 8.5 | 8.0 | 10.4 | 11.1 |
| Operating margin | 16.7% | 11.1% | 10.2% | 10.9% | 12.4% | 10.5% |
| Other income | 0.3 | 1.2 | 1.1 | 1.0 | 1.0 | 1.1 |
| Interest | 1.1 | 1.1 | 1.6 | 2.1 | 1.6 | 1.2 |
| Depreciation | 1.2 | 1.4 | 1.5 | 1.8 | 1.6 | 1.5 |
| Profit before tax | 8.3 | 6.9 | 6.5 | 5.1 | 8.3 | 9.5 |
| Tax | 2.0 | 1.7 | 1.6 | 2.1 | 1.8 | 1.8 |
| Net profit | 0.0 | 0.0 | 0.0 | 3.7 | 5.6 | 6.5 |
| EPS ₹ | 4.46 | 3.66 | 3.17 | 2.57 | 3.59 | 4.20 |
| Revenue YoY | — | — | 35.0% | -2.0% | 1.3% | 45.2% |
| Profit YoY | — | — | — | — | — | 75.1% |
Returns & margins
trailing-twelve-month, per half year| H2 FY24 | H1 FY25 | H2 FY25 | H1 FY26 | H2 FY26 | |
|---|---|---|---|---|---|
| ROE | 0.0% | 0.0% | 3.4% | 8.1% | 10.0% |
| ROCE | 32.3% | 29.8% | 9.4% | 13.3% | 14.3% |
| Net margin | 0.0% | 0.0% | 2.4% | 6.0% | 6.4% |
| EBITDA margin | 13.7% | 10.6% | 10.5% | 11.7% | 11.4% |
| Debt / equity | 0.00 | 0.00 | 0.47 | 0.12 | 0.19 |
| Interest coverage | 7.95 | 5.96 | 4.15 | 4.67 | 7.37 |
| Asset turnover | 1.33 | 1.54 | 0.78 | 0.83 | 1.08 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '23 | MAR '25 | SEP '25 | MAR '26 | |
|---|---|---|---|---|
| Share capital | 13.9 | 15.6 | 15.6 | 15.6 |
| Other equity / reserves | 40.0 | 93.9 | 99.2 | 105.5 |
| Total equity | 53.9 | 109.5 | 114.8 | 121.0 |
| Borrowings | 0.0 | 51.9 | 13.6 | 22.9 |
| Current liabilities | 37.7 | 63.6 | 44.8 | 28.7 |
| Non-current liabilities | 9.0 | 10.0 | 13.8 | 7.8 |
| Total assets | 102.0 | 198.4 | 189.7 | 174.9 |
| Property, plant & equipment | 18.9 | 20.8 | 20.2 | 20.1 |
| Capital work-in-progress | 0.0 | — | — | — |
| Investments | 0.0 | 29.0 | 29.0 | 29.0 |
| Inventories | 19.2 | 44.2 | 60.0 | 39.0 |
| Receivables | 28.6 | 33.8 | 45.1 | 31.5 |
| Cash & equivalents | 12.8 | 11.5 | 13.3 | 3.0 |
Cash flow
annual · ₹ crore · line = free cash flow| FY24 | FY25 | FY26 | |
|---|---|---|---|
| Cash from operations | -13.0 | -29.2 | 33.7 |
| Cash from investing | -3.8 | -27.2 | -7.2 |
| Cash from financing | 22.8 | 79.3 | -31.6 |
| Capex | 3.5 | 8.7 | 9.7 |
| Free cash flow | -16.6 | -37.8 | 24.1 |
| Dividends paid | 0.0 | 0.0 | 0.0 |
Where the assets sit
Mar '26 · ₹ crorePeer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Infinium Pharmachem Limited | 435 | 279.15 | 35.8 | 3.59 | 10.0% |
StoxGud checklist: Neutral setup · 5/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Infinium Pharmachem Limited?
Infinium Pharmachem Limited (INFINIUM) closed at ₹279.15 on NSE on 06 Nov 2026.
What is the market cap of Infinium Pharmachem Limited?
₹435 crore at the latest close.
What is the P/E ratio of Infinium Pharmachem Limited?
35.8, on trailing-twelve-month earnings from its filings.
How fast is Infinium Pharmachem Limited growing?
Infinium Pharmachem Limited: Latest-half-year revenue is up 45.2% year on year, profit up 75.1%.
How profitable is Infinium Pharmachem Limited?
On a trailing-twelve-month basis return on equity is 10.0%, return on capital employed 14.3%, operating margin 11.4%, net margin 6.4%.
How much debt does Infinium Pharmachem Limited have?
Infinium Pharmachem Limited is lightly geared: debt to equity is 0.19 with borrowings of ₹23 cr against cash of ₹3 cr (balance sheet of 2026-03-31). Operating profit covers interest 7.4 times.
Financials parsed from Infinium Pharmachem Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Half-yearly from H1 FY24, annual from FY24, balance sheet from Sep '23. * = derived (full year minus the other half). This company is on NSE's SME platform and reports results half-yearly. Information only, not investment advice.